Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer

Molecular Therapy

Volumn 5, Issue 3, 2002, Pages 223-232

  Zhang, Liqun ^a   Adams, Jason Yeates ^a   Billick, Erika ^a   Ilagan, Romyla ^a   Iyer, Meera ^a   Le, Kim ^a   Smallwood, Andrea ^a   Gambhir, Sanjiv S ^a   Carey, Michael ^a   Wu, Lily ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Charge coupled device; GAL4 VP16; Gene therapy; Imaging; Prostate cancer; TSTA

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CELL EXTRACT; CHIMERIC PROTEIN; DNA BINDING PROTEIN; FUNGAL PROTEIN; HYBRID PROTEIN; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIAGNOSTIC IMAGING; DNA TEMPLATE; ENHANCER REGION; FEMALE; GENE ACTIVITY; GENE AMPLIFICATION; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENETIC ANALYSIS; GENETIC ENGINEERING; GENETIC TRANSFECTION; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLASMID; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; REPORTER GENE; TARGET CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSGENE;

ANIMALIA; CYTOMEGALOVIRUS; MUS MUSCULUS;

EID: 0036192826     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0551     Document Type: Article

References (44)

1. Gene therapy: Trials and tribulations
2. Gene therapy for prostate cancer
3. Human gene therapy
4. Gene therapy: Principles and potential
5. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system
6. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
7. Prostate-specific antigen expression is regulated by an upstream enhancer
8. Molecular analysis of the prostate-specific antigen upstream gene enhancer
9. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer
10. Cooperative assembly of androgen receptor into a nucleo-protein complex that regulates the prostate-specific antigen enhancer
11. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells
12. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer
13. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression
14. Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin-releasing hormone expression and actions in human inflammatory arthritis
15. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors
16. Gene therapy: Designer promoters for tumour targeting
17. GAL4-VP16 is an unusually potent transcriptional activator
18. A mechanism for synergistic activation of a mammalian gene by GAL4 derivatives
19. GAL4 activates transcription in Drosophilia
20. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
21. Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy
22. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters
23. Imaging transgene expression with radionuclide imaging technologies
24. Management of advanced prostate cancer
25. Prostate cancer: Molecular biology of early progression to androgen independence
26. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
27. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP
28. Negative effect of the transcriptional activator GAL4
29. Tracing transgene expression in living zebrafish embryos
30. A synergistic increase in potency of a multimerized VP16 transcriptional activation domain
31. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
32. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice
33. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters
34. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
35. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter
36. Imaging transgene expression in live animals
37. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography
38. Seeing is believing: Non-invasive, quantitative and repetitive imaging of reporter gene expression in living animals, using positron emission tomography
39. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir
40. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines
41. Activation of mitogen-activated protein kinase associated with prostate cancer progression
42. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells
43. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways
44. A potent GAL4 derivative activates transcription at a distance in vitro